CCN2 and idiopathic pulmonary fibrosis: Another prematurely interrupted RCT was the randomized, double-blind, placebo-controlled, multicenter phase-3 ZEPHYRUS trial, which aimed to assess the efficacy and safety of pamrevlumab—a connective-tissue-growth-factor (CTGF) inhibitor in patients with IPF.